Inactive Instrument

News Provectus Biopharmaceuticals Inc Nyse

Equities

US74373P1084

End-of-day quote Nyse Other stock markets
- ^USD	-

Apr. 16	Provectus Biopharmaceuticals, Inc. Appoints Dominic Rodrigues as President	CI
Apr. 16	Provectus Biopharmaceuticals, Inc. Appoints Ed Pershing as Chief Executive Officer	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers	08:01am	AQ
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation	Apr. 16	AQ
Provectus Biopharmaceuticals, Inc. Appoints Dominic Rodrigues as President	Apr. 16	CI
Provectus Biopharmaceuticals, Inc. Appoints Ed Pershing as Chief Executive Officer	Apr. 16	CI
Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting	Apr. 11	AQ
Provectus Biopharmaceuticals, Inc. Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting	Apr. 11	CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium	Mar. 27	AQ
Provectus Biopharmaceuticals, Inc. Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium	Mar. 27	CI
Provectus Biopharmaceuticals, Inc. Announces Management Changes	Mar. 26	CI
Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines	Mar. 12	AQ
Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting	Mar. 07	AQ
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PHARMACEUTICAL-GRADE ROSE BENGAL SODIUM ABSTRACT FOR POSTER PRESENTATION AT 2024 SOCIETY FOR INVESTIGATIVE DERMATOLOGY ANNUAL MEETING	Mar. 01	AQ
Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting	Feb. 29	AQ
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call	Feb. 15	AQ
Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services	Feb. 14	AQ
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant	Dec. 18	AQ
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma	Nov. 15	AQ
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy Pv-10 for Advanced Cutaneous Melanoma	Nov. 15	CI
Provectus: Q3 Earnings Snapshot	Nov. 14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Provectus Biopharmaceuticals Inc Nyse

Equities

US74373P1084

Summary

Filters